Advanced search
Publication Cover
Blood and Lymphatic Cancer: Targets and Therapy Volume 13, 2023 - Issue
Submit an article Journal homepage
156
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases

Jing Wang1 Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, FL, 32224, USAORCID Iconhttps://orcid.org/0000-0002-8296-2961
ORCID Icon,
Firas Baidoun2 Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA
,
Han W Tun2 Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USAORCID Iconhttps://orcid.org/0000-0002-9184-094X
ORCID Icon &
Muhamad Alhaj Moustafa2 Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8582-1219
ORCID Icon
Pages 59-65 | Received 23 Dec 2022, Accepted 07 Sep 2023, Published online: 03 Oct 2023

References

  • Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398
  • Hallek M, Al‐Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705. doi:10.1002/ajh.26367
  • Jain N, Wierda W, Ferrajoli A, et al. A phase 2 study of yttrium‐90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009;115(19):4533–4539. doi:10.1002/cncr.24522
  • Small S, Ma S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll): targeted therapy vs. chemoimmunotherapy. Curr Hematol Malig Rep. 2021;16(4):325–335. doi:10.1007/s11899-021-00637-1
  • Emmanouilides, CE. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol. 2003;22:595.
  • Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-hodgkin’s lymphoma. Clin Med Res. 2005;3(3):157–165. doi:10.3121/cmr.3.3.157
  • Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2(3):p. 457–70.
  • Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67(1):134–140. doi:10.1172/JCI110005
  • Alhaj Moustafa M, Peterson J, Hoppe BS, et al. Real world long-term follow-up experience with Yttrium-90 ibritumomab tiuxetan in previously untreated patients with low-grade follicular lymphoma and marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(8):618–625. doi:10.1016/j.clml.2022.03.004
  • Hendrix CS, de Leon C, Dillman RO. Radioimmunotherapy for non-hodgkin’s lymphoma with yttrium 90 ibritumomab tiuxetan. Clin J Oncol Nurs. 2002;6(3):144–148. doi:10.1188/02.CJON.144-148
  • Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol. 2003;21(7):1263–1270. doi:10.1200/JCO.2003.08.043
  • DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Nucl Med. 1999;40(8):1317–1326.
  • DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin’s lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80(S12):2706–2711.
  • Kaminski MS, Press OW, Lister TA, Valente NK, Kroll S, Tidmarsh G. Iodine I131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience. Blood. 1999;88:1.
  • Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of Yttrium-90–labeled Ibritumomab Tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(10):p. 2453–2463. doi:10.1200/JCO.2002.11.076
  • Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285–4292. PMID: 17709799. doi:10.1200/JCO.2006.09.2882
  • Alhaj Moustafa M, Parrondo R, Wiseman G, Peterson J, Witzig TE, Tun HW. Long-term outcome of patients with low-grade follicular lymphoma treated with Yttrium-90 Ibritumomab tiuxetan: the Mayo clinic experience. Am Soc Hematol. 2019;2019:1. doi:10.1182/blood-2019-129391
  • Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19(19):3918–3928. PMID: 11579112. doi:10.1200/JCO.2001.19.19.3918.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.